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Abstract
Introduction: Previous research in the Nurses’ Health Study (NHS) and the NHSII observed that, among women
diagnosed with benign breast disease (BBD), those with predominant type 1/no type 3 lobules (a marker of
complete involution) versus other lobule types were at lower risk of subsequent breast cancer. Studies in animal
models suggest that insulin-like growth factor-1 (IGF-1) may inhibit involution of lobules in the breast; however,
this has not been studied in humans.
Methods: We conducted a cross-sectional study among 472 women in the NHSII who were diagnosed with
biopsy-confirmed proliferative BBD between 1991 and 2002 and provided blood samples between 1996 and 1999.
A pathologist, blinded to exposure status, classified lobule type in normal adjacent tissue on available biopsy slides
according to the number of acini per lobule. For each participant, the pathologist determined the predominant
lobule type (that is, type 1, type 2, or type 3) and whether any type 1 or any type 3 lobules were present. Lobule
type was then classified as: predominant type 1/no type 3 lobules, which is suggestive of complete involution; or
other lobule types. Multivariate logistic models were used to assess the associations between plasma IGF-1, insulin-
like growth factor binding protein-3 (IGFBP-3), and the ratio of IGF-1:IGFBP-3 levels with lobule type.
Results: In univariate analyses, greater age, higher body mass index, postmenopausal status, nulliparity, and lower
IGF-1 levels were associated with predominant type 1/no type 3 lobules (P < 0.05). In multivariate models adjusting
for age and assay batch, higher IGF-1 levels were associated with decreased odds of predominant type 1/no type
3 lobules (odds ratio quartile 4 vs. quartile 1 = 0.37, 95% confidence interval = 0.15 to 0.89). Greater ratios of IGF-1:
IGFBP-3 levels were also associated with decreased odds of predominant type 1/no type 3 lobules (odds ratio
quartile 4 vs. quartile 1 = 0.26, 95% confidence interval = 0.11 to 0.64). These results were slightly attenuated after
adjustment for other potential predictors of lobule type.
Conclusions: Higher IGF-1 levels and a greater IGF-1:IGFBP-3 ratio were associated with decreased odds of having
predominant type 1 lobules/no type 3 lobules among women with proliferative BBD in the NHSII. This study provides
further evidence for the role of insulin-like growth factors in the structure of breast lobules and lobular involution.
Introduction
Breast tissue in women undergoes transformation
throughout puberty, pregnancy, and breastfeeding, and
with aging. During puberty, type 1 immature lobules dif-
ferentiate into type 2 lobules, which further differentiate
into type 3 lobules during pregnancy [1]. Type 4 lobules
with milk-producing acini are present during lactation,
but subsequently undergo involution to type 3 lobules
after cessation of breastfeeding [2]. The differentiation
of breast lobules during pregnancy and lactation may
explain, in part, why these factors are associated with a
lower risk of breast cancer [2]. Interestingly, beginning
around age 40 an age-related involution also occurs, in
which differentiated lobules in the breast regress to
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any medium, provided the original work is properly cited.earlier structures [1]. Although they appear histologically
similar, type 1 lobules in parous women whose breasts
have undergone differentiation and involution may be
biologically different from those in nulliparous women,
and may be less susceptible to carcinogens [2]. In a pre-
vious case-control study nested in the Nurses’ Health
Study (NHS) and the NHSII, having predominant type
1/no type 3 lobules - a marker of complete involution -
was associated with a decreased risk of subsequent
breast cancer among women with benign breast disease
(BBD) [3]. In addition, studies in the Mayo BBD cohort
reported that the increasing acini per lobule and no or
partial lobular involution were associated with a higher
risk of breast cancer [4,5]. However, little is known
about potential exposures that may alter the degree of
involution/lobule type.
Data from animal studies indicate that insulin-like
growth factor 1 (IGF-1) may inhibit involution [6]. IGF-
1 is mitogenic and anti-apoptotic, and has been identi-
fied as a factor in tumor development and progression
[7,8]. Evidence from epidemiologic studies as well as
animal studies suggests that elevated IGF-1 levels
increase the risk of mammary tumors [9,10]. In addition,
IGF-1 levels have been associated with a number of
breast cancer risk factors, including birth weight, child-
hood body size, and mammographic density [11,12].
However, no studies to date have examined the associa-
tion between IGF-1 levels and involution or lobule type
in women. The purpose of this study was to examine
the association of IGF-1 and insulin-like growth factor
binding protein-3 (IGFBP-3) levels and their ratio with
lobule type among women with BBD in the NHSII.
Materials and methods
Study population
The NHSII began in 1989, when 116,430 female regis-
tered nurses, aged 25 to 42, from 14 US states com-
pleted an initial questionnaire. The cohort has been
followed by biennially mailed questionnaires to update
exposure and covariate information as well as to ascer-
tain incident diseases.
Between 1996 and 1999, 29,611 NHSII members who
were free of cancer in 1995 and between 32 and 45
years of age provided a blood sample. Characteristics of
this cohort and blood collection details have been pre-
viously described [13]. Briefly, premenopausal women
who had not taken any type of hormones, been preg-
nant, or breastfed in the previous 6 months (n = 18,521)
provided an initial 15-ml blood sample drawn on the
third to fifth day of their menstrual cycle (follicular
blood draw) and a second 30-ml blood sample drawn 7
to 9 days before the anticipated start of their next cycle
(luteal blood draw). The day of the luteal blood collec-
tion, the woman shipped both the follicular and luteal
blood samples to our laboratory with an ice-pack, via
overnight courier, where the samples were processed,
separated into plasma, red blood cell, and white blood
cell components, and aliquoted into labeled cryotubes.
Women who were ineligible to provide timed samples
(that is, perimenopausal, postmenopausal, had under-
gone a simple hysterectomy, or currently used oral con-
traceptives or other hormones) or declined to give
timed samples (n = 11,090) provided a single 30-ml
blood sample (referred to as untimed samples). These
samples were shipped and processed similarly to the
timed samples.
All samples have been stored in the vapor phase of
continuously monitored liquid nitrogen freezers (< 130°
C) since collection. The study was approved by the
Committee on the Use of Human Subjects in Research
at the Brigham and Women’s Hospital. Informed con-
sent was implied by receipt of completed questionnaires
and blood samples.
Benign breast disease cases
At each questionnaire cycle, participants were asked
whether they were diagnosed with BBD and whether the
diagnosis was confirmed by biopsy or aspiration. A total
of 1,145 women in the blood subcohort reported a first
diagnosis of biopsy-confirmed BBD on the 1993 through
2001 questionnaires. Of these 1,145 women, 968 (85%
of those eligible) confirmed the diagnosis of BBD and
granted permission for review of their biopsy records
and pathology specimens. Adequate pathology material
w a so b t a i n e df r o mh o s p i t a l sa n dr e v i e w e df o r8 5 8
women (89% of those who gave permission), and 841 of
these (98% of those reviewed) were confirmed by histo-
logic review to be valid BBD cases. Of these, 536 (64%)
were classified as proliferative BBD. An additional 64
women were excluded for various reasons, including not
having enough plasma or having reported a diagnosis of
cancer prior to BBD diagnosis. In total, 472 women with
proliferative BBD were included in the current analysis.
Laboratory assays
IGF-1 and IGFBP-3 levels were assayed in the Depart-
ment of Medicine and Oncology at McGill University
using ELISA with reagents from Diagnostic Systems
Laboratory (Webster, TX, USA). IGF-1 was measured in
randomly ordered luteal and untimed samples. IGF-1
and IGFBP-3 were assayed for BBD cases diagnosed
between 1991 and 1997 as part of a prior study on IGF-
1 and proliferative BBD risk [14]. IGF-1 and IGFBP-3
were assayed in a second batch for women diagnosed
with proliferative BBD between 1997 and 2002 to incor-
porate later follow-up cycles and increase the sample
size. The mean time between blood collection and
biopsy was 3.4 years for the first batch and 1.9 years for
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IGFBP-3, and the IGF-1:IGFBP-3 ratio quartiles by
batch are presented in Supplemental Table 1 in Addi-
tional file 1. The mean coefficients of variation from
masked replicate quality control samples included in
each batch were 3.5 and 2.8% for IGF-1 and were 1.6
and 3.7% for IGFBP-3.
Lobule type
A study pathologist (JLC), blinded to exposure status,
reviewed biopsy slides for the 472 women diagnosed
with proliferative BBD who were included in the study.
Lobules were classified according to the number of acini
per lobule based on Russo and Russo’sw o r k[ 2 ] .O n
average, type 1 lobules had fewer than 12 acini, type 2
lobules had approximately 50 acini, and type 3 lobules
had approximately 80 acini. The pathologist classified
which lobule type was predominant (that is, type 1, type
2, or type 3) and determined whether there were any
type 1 or type 3 lobules present for each specimen. For
each participant, the lobule type was classified into one
of the following two categories: predominant type 1/no
type 3 lobules, or other lobule type. These categories
were selected based on our previous study that found
women with predominant type 1 and no type 3 lobules
had a lower risk of subsequent breast cancer compared
with women with other lobule types [3]. Biopsy slides
were reviewed in two batches: BBD cases diagnosed
Table 1 Characteristics of study population by lobule type in women with benign breast disease
No type 1 lobules or mixed lobule types (n = 398) Predominant type 1 and no type 3 lobules (n = 74)
Age at biopsy (years) 41.5 (4.6) 44.2 (5.8)
Body mass index (kg/m
2) 25.6 (5.7) 28.0 (8.0)
Parity (among parous) 2.3 (0.8) 2.4 (1.0)
Age at first birth (among parous) 26.2 (4.1) 26.2 (4.7)
Height 64.8 (2.5) 64.5 (2.2)
Nulliparous 62 (15.6%) 20 (27.0%)
Family history of breast cancer 46 (11.6%) 6 (8.1%)
Ever use oral contraceptive 332 (83.4%) 64 (86.5%)
Menopausal status
Premenopausal/dubious 343 (86.2%) 54 (73.0%)
Postmenopausal, no PMH 41 (10.3%) 15 (20.3%)
Postmenopausal, PMH 14 (3.5%) 5 (6.8%)
Alcohol
None 176 (44.2%) 25 (33.8%)
0 to < 1.5 g/day 68 (17.1%) 15 (20.3%)
1.5 to < 4.5 g/day 85 (21.4%) 14 (18.9%)
4.5+ g/day 69 (17.3%) 20 (27.0%)
Age at menarche
< 11 years 81 (20.4%) 18 (24.3%)
12 years 123 (30.9%) 22 (29.7%)
13 years 113 (28.4%) 19 (25.7%)
14+ years 81 (20.4%) 15 (20.3%)
Histologic categories of benign breast disease
Proliferative with no atypia 365 (91.7%) 65 (87.8%)
Atypical hyperplasia 33 (8.3%) 9 (12.2%)
Insulin-like growth factor 1
Quartile 1 93 (23.4%) 24 (32.4%)
Quartile 2 98 (24.6%) 20 (27.0%)
Quartile 3 98 (24.6%) 20 (27.0%)
Quartile 4 109 (27.4%) 10 (13.5%)
Insulin-like growth factor binding protein-3
Quartile 1 95 (23.9%) 22 (29.7%)
Quartile 2 99 (24.9%) 19 (25.7%)
Quartile 3 101 (25.4%) 17 (23.0%)
Quartile 4 103 (25.9%) 16 (21.6%)
Data from the Nurses’ Health Study II (1991 to 2002) presented as mean (standard deviation) or n (%). PMH, postmenopausal hormones.
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diagnosed between 1997 and 2001 (second batch). To
assess whether lobule-type assessment was consistent
across batches, the pathologist reclassified 50 first-batch
slides at the time of reading for the second batch. The
percentage agreement between the two readings for our
two-category lobule-type classification was 78%. ok
Covariate data
We obtained information on potential correlates of
lobule type from biennial NHSII questionnaires. Respon-
dents provided information on age at menarche and
height in 1989. Family history of breast cancer was
ascertained in 1989 and 1997. Parity, age at first birth,
alcohol use, menopausal status, weight, and oral contra-
ceptive use were assessed biennially. For covariates with
multiple assessments, we used information from the
questionnaire completed closest to BBD biopsy.
Statistical analysis
We examined the distribution of breast cancer risk fac-
tors according to lobule type using univariate logistic
regression. For our primary analyses we defined the out-
come as predominant type 1/no type 3 lobules. Multi-
v a r i a t el o g i s t i cr e g r e s s i o nw a su s e dt oe s t i m a t eo d d s
ratios (ORs) and 95% confidence intervals (CIs) for the
association between having predominant type 1/no type
3 lobules (vs. other lobule types) and batch-specific
quartiles of IGF-1, IGFBP-3, and the ratio of IGF-1:
IGFBP-3. Our primary model adjusted for age at biopsy
(continuous) and assay batch, with subsequent models
additionally adjusting for potential correlates of lobule
type including body mass index, menopausal status/
postmenopausal hormone use, presence of atypia, parity,
alcohol, IGFBP-3 (for the IGF-1 analysis), and IGF-1
(for the IGFBP-3 analysis).
To test for trend, we modeled the square root of IGF-1
levels and the square root of the IGF-1:IGFBP-3 ratio as
continuous variables due to their skewed distribution.
Untransformed IGFBP-3 levels were modeled linearly to
test for trend. We did not detect any statistical outliers for
IGFBP-3 levels or the square root of IGF-1 levels or the
square root of the IGF-1:IGFBP-3 ratio using the general-
ized extreme studentized deviate many-outlier approach
[15]. In sensitivity analyses, we restricted our study popu-
lation to parous women and to premenopausal women.
Since results did not vary by batch (P for interaction >
0.60), all women were combined in the analyses. We used
SAS 9.2 software (SAS Institute, Cary, NC, USA) for all
analyses and present two-sided P values. ok
Results
Ninety-six (20.3%) women were classified as predomi-
nant lobule type 1, 318 (67.4%) were classified as
predominant lobule type 2, and 56 (11.9%) were classi-
fied as predominant lobule type 3. Study pathologists
were unable to classify the predominant lobule type for
two women (0.4%). Most women had any type 1 lobules
present (n = 442, 93.6%) and about one-half had any
type 3 lobules present (n = 238, 50.4%). Seventy-four of
the 472 (16%) women in the study were classified as
having predominant type 1/no type 3 lobules (Table 1).
These women were older at biopsy and had a higher
body mass index than women with other lobule types.
In addition, women with predominant type 1/no type 3
l o b u l e sw e r em o r el i k e l yt ob en u l l i p a r o u sa n d
postmenopausal.
After adjusting for age and assay batch, women in the
highest quartile of IGF-1 had a 63% lower odds of hav-
ing predominant type 1/no type 3 lobules compared
with women in the lowest quartile (OR = 0.37, 95% CI
= 0.15 to 0.89; Ptrend = 0.01) (Table 2). Additional
adjustment for correlates of lobule type and IGFBP-3
slightly attenuated the OR (OR = 0.39, 95% CI = 0.13 to
1.18, Ptrend = 0.07). Women in the second and third
quartiles of IGF-1 levels had a similar odds of having
predominant type 1/no type 3 lobules compared with
women in the lowest quartile (OR = 0.92 95% CI = 0.41
to 2.05 and OR = 0.98, 95% CI = 0.41 to 2.31,
respectively).
We observed a stronger association between the IGF-
1:IGFBP-3 ratio and lobule type, with women in the
highest quartile of IGF-1:IGFBP-3 having a 74%
decreased odds of predominant type 1/no type 3 lobules
compared with women in the lowest quartile (OR =
0.26, 95% CI = 0.11 to 0.64; Ptrend = 0.01) (Table 3).
This association was slightly attenuated after adjustment
for correlates of lobule type (OR = 0.32, 95% CI = 0.12
to 0.83; Ptrend = 0.09). Women in the second and third
quartiles of IGF-1:IGFBP-3 levels had a nonstatistically
significant decreased odds of predominant type 1/no
type 3 lobules compared with women in the lowest
quartile (OR = 0.83, 95% CI = 0.39 to 1.76 and OR =
0.75, 95% CI = 0.33 to 1.71, respectively).
We did not detect a statistically significant association
between IGFBP-3 and lobule type (OR top vs. bottom
IGFBP-3 quartile = 0.71, 95% CI = 0.33 to 1.51, Ptrend =
0.48) (Table 4).
We observed similar associations when we restricted
our study population to premenopausal women (n =
397) or parous women (n = 390). Owing to the smaller
sample size, however, the results were not statistically
significant (data not shown).
Discussion
In this analysis of women with BBD, we observed an
inverse association between plasma IGF-1 and the IGF-
1:IGFBP-3 ratio with predominant type 1/no type 3
Rice et al. Breast Cancer Research 2012, 14:R44
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quartile were associated with a decreased odds of predo-
minant type 1/no type 3 lobules, suggesting a potential
threshold effect. However, we observed more of a linear
trend for the IGF-1:IGFBP-3 ratio, which may better
represent available IGF-1. The results did not materially
change when we restricted our analysis to parous
women or premenopausal women (Supplemental Tables
2 to 4 in Additional file 1).
Our findings are consistent with a study reporting that
transgenic mice with IGF-1 overexpression in mammary
tissue had inhibited postlactational involution [6]. In
vivo studies in animals suggest that inhibition of postlac-
tational involution increases the risk of subsequent
mammary tumors [16]. In addition, recent studies in
women have found that lobule type or degree of age-
related involution is associated with breast cancer risk.
For example, in the NHS and the NHSII, women with
predominant type 1/no type 3 lobules had a 29%
decreased risk of breast cancer compared with women
with other lobule types [3]. Another study did not detect
an association between lobule type and breast cancer
risk, but the methodology used in the two studies dif-
fered [17]. For example, Ramakrishnan and colleagues
only assessed the predominant lobule type after the
diagnosis of breast cancer in the cases, whereas the
NHS/NHSII assessed all lobule types before diagnosis
[17].
In the Mayo Clinic BBD cohort, increasing acini per
lobule was associated with a stepwise increase in breast
cancer risk (P = 0.0004). For example, women with
more than an average of 40 acini per lobule had 11.9
times the odds of developing breast cancer compared
with women with 10 or fewer average acini per lobule
[5]. In addition, the acinar count was associated with
t h ed e g r e eo fi n v o l u t i o na sa s s e s s e db yap a t h o l o g i s t .
Women with complete involution, on average, had 7.7
acini per lobule versus 32 acini per lobule among
w o m e nw i t hn oi n v o l u t i o n[ 5 ] .F u r t h e r ,i nt h i ss a m e
cohort, women with no involution had a significantly
increased risk of breast cancer than women with com-
plete involution when compared with rates in the Iowa
SEER [4].
Interestingly, degree of involution has been associated
with mammographic density, which itself is a strong risk
factor for breast cancer [18,19]. In the Mayo BBD
cohort, women with no or partial involution were more
likely to have a high density pattern than women with
complete involution (Ptrend <0 . 0 1 ) ,a l t h o u g hb o t hd e n -
sity and involution were independent predictors of
breast cancer [20]. Similarly, in premenopausal women,
IGF-1 levels have been positively associated with percen-
tage density in some studies [11,21,22], but not all [23].
In general, IGF-1 levels have not been associated with
percentage density among postmenopausal women
[11,21,23,24]. These data, in conjunction with the results
Table 2 Predominant type 1/no type 3 lobules according to batch-specific quartiles of plasma IGF-1
IGF-1 (ng/ml)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P value
Predominant type 1, no type 3/other lobule type (n) (24/93) (20/98) (20/98) (10/109)
Age and batch-adjusted
a 1 (reference) 0.82 (0.40 to 1.67) 0.84 (0.41 to 1.76) 0.37 (0.15 to 0.89) 0.01
Multivariate model 1
b 1 (reference) 0.98 (0.46 to 2.07) 1.06 (0.49 to 2.29) 0.47 (0.19 to 1.17) 0.08
Multivariate model 2
c 1 (reference) 0.94 (0.44 to 2.01) 1.00 (0.46 to 2.19) 0.41 (0.16 to 1.04) 0.05
Multivariate model 3
d 1 (reference) 0.92 (0.41 to 2.05) 0.98 (0.41 to 2.31) 0.39 (0.13 to 1.18) 0.07
Data (vs. other types) from the Nurses’ Health Study II presented as odds ratio (95% confidence interval) unless stated otherwise.
aAge at biopsy (continuous),
insulin-like growth factor 1 (IGF-1) batch.
bAge at biopsy (continuous), IGF-1 batch, body mass index (continuous), menopausal status (premenopausal/dubious;
postmenopausal, no postmenopausal hormone use; postmenopausal, postmenopausal hormone use), histological category of benign breast disease (proliferative
without atypia, proliferative with atypia).
cMultivariate model 1 plus parity (nulliparous, parous), alcohol (none, < 1.5, 1.5 to 4.5, 4.5+ g/day).
dMultivariate model 2
plus insulin-like growth factor binding protein-3 (continuous).
Table 3 Predominant type 1/no type 3 lobules according to batch-specific quartiles of plasma IGF-1:IGFBP-3 ratios
IGF-1:IGFBP-3 ratio
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P value
Predominant type 1, no type 3/other lobule type (n) (27/90) (20/98) (18/100) (9/110)
Age and batch-adjusted
a 1 (reference) 0.68 (0.33 to 1.39) 0.60 (0.29 to 1.26) 0.26 (0.11 to 0.64) 0.01
Multivariate model 1
b 1 (reference) 0.80 (0.38 to 1.67) 0.75 (0.34 to 1.66) 0.34 (0.13 to 0.86) 0.10
Multivariate model 2
c 1 (reference) 0.83 (0.39 to 1.76) 0.75 (0.33 to 1.71) 0.32 (0.12 to 0.83) 0.09
Data from the Nurses’ Health Study II presented as odds ratio (95% confidence interval) unless stated otherwise.
aAge at biopsy (continuous), insulin-like growth
factor 1 (IGF-1):insulin-like growth factor binding protein-3 (IGFBP-3) batch.
bAge at biopsy (continuous), IGF-1:IGFBP-3 batch, body mass index (continuous),
menopausal status (premenopausal/dubious; postmenopausal, no postmenopausal hormone use; postmenopausal, postmenopausal hormone use), histological
category of benign breast disease (proliferative without atypia, proliferative with atypia).
cMultivariate model 1 plus parity (nulliparous, parous), alcohol (none, <
1.5, 1.5 to 4.5, 4.5+ g/day).
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bit involution in female breast tissue as well as increase
mammographic density. Further research is needed to
understand the timing of IGF-1 exposure in relation to
morphologic changes in breast tissue as well as the
inter-relationship between involution and mammo-
graphic density.
Our study has several limitations. First, we only have a
single measurement of IGF-1 and IGFBP-3 levels, which
may not be representative of typical levels. However, the
3-year intraclass correlation coefficient among premeno-
pausal women in the NHSII was 0.70 for IGF-1 and
0.74 for IGFBP-3, irrespective of menstrual cycle phase.
These data suggest that a single measurement of IGF-1
and IGFBP-3 is representative of levels over at least a 3-
year period. Lobule type was assessed within 3 years of
blood draw for 56% of participants and within 5 years of
blood draw for 85%; IGF-1 or IGFBP-3 levels at the
time of blood draw are therefore probably representative
of those at the time of lobule type assessment. Any mis-
classification of hormone levels should be nondifferen-
tial as the laboratory was blinded to lobule type.
Another limitation is that we did not directly assess the
degree of involution of lobules in the breast, but rather
ascertained lobule type from benign biopsy specimens.
However, we have previously reported that women with
predominant type 1 and no type 3 lobules, who have
probably undergone age-related involution, have a lower
risk of breast cancer than women who have other lobule
types and thus have probably not undergone age-related
involution. Lobule type was assessed on benign breast
biopsy specimens, which may not be representative of
lobule type throughout the breast given the small size of
some of the specimens. Ok However, at least one study
has shown that the extent of involution is similar across
different quadrants of the breast, indicating that predo-
minant lobule type on a single biopsy specimen is likely
to be representative of lobule type throughout the breast
[25]. However, there is likely to be some misclassifica-
tion of lobule type. Any misclassification should be
nondifferential since pathologists were blinded to IGF-1
and IGFBP-3 levels, potentially attenuating our results.
Finally, our study was cross-sectional so we were unable
to prospectively assess whether IGF-1 levels measured
prior to biopsy predicted the lobule type or degree of
involution.
The strengths of our study include the centralized
pathology review of benign biopsy specimens, high-qual-
ity IGF-1 and IGFBP-3 assays, and detailed adjustment
for correlates of lobule type.
Conclusion
Higher IGF-1 levels as well as greater IGF-1:IGFBP-3
ratios were associated with a decreased odds of predo-
minant type 1/no type 3 lobules among women with
BBD in the NHSII. While this study provides important
evidence for the role of insulin-like growth factors in
the microscopic anatomy of the breast lobules, further
research is needed to elucidate the relationship between
hormones, such as IGF-1 and IGFBP-3, and age-related
lobular involution in women.
Additional material
Additional file 1: Supplemental Table 1 showing the ranges and
medians of IGF-1, IGFBP-3, and the IGF-1:IGFBP-3 ratio quartiles by
batch, NHSII. Supplemental Table 2 showing the odds ratios (95%
confidence intervals) of predominant type 1/no type 3 lobules (vs. other
types) according to quartiles of plasma IGF-1 among parous women and
premenopausal women only, NHSII. Supplemental Table 3 showing the
odds ratios (95% confidence intervals) of predominant type 1/no type 3
lobules according to quartiles of plasma IGF-1:IGFBP-3 ratios among
parous women and premenopausal women only, NHSII. Supplemental
Table 4 showing the odds ratios (95% confidence intervals) of
predominant type 1/no type 3 lobules (vs. other types) according to
quartiles of plasma IGFBP-3 among parous women or premenopausal
women only, NHSII.
Abbreviations
BBD: benign breast disease; ELISA: enzyme-linked immunosorbent assay; IGF-
1: insulin-like growth factor 1; IGFBP-3: insulin-like growth factor binding
protein-3; NHS: Nurses’ Health Study.
Table 4 Predominant type 1/no type 3 lobules according to batch-specific quartiles of plasma IGFBP-3
IGFBP-3 (ng/ml)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P value
Predominant type 1, no type 3/other lobule type (n) (22/95) (19/99) (17/101) (16/103)
Age and batch-adjusted
a 1 (reference) 0.83 (0.40 to 1.70) 0.75 (0.36 to 1.57) 0.71 (0.33 to 1.51) 0.48
Multivariate model 1
b 1 (reference) 0.95 (0.45 to 1.99) 0.83 (0.39 to 1.78) 0.67 (0.31 to 1.45) 0.47
Multivariate model 2
c 1 (reference) 0.87 (0.41 to 1.87) 0.84 (0.39 to 1.83) 0.61 (0.28 to 1.35) 0.39
Multivariate model 3
d 1 (reference) 1.06 (0.48 to 2.37) 1.17 (0.48 to 2.81) 0.93 (0.36 to 2.41) 0.63
Data (vs. other types) from the Nurses’ Health Study II presented as odds ratio (95% confidence interval) unless stated otherwise.
aAge at biopsy (continuous),
insulin-like growth factor binding protein-3 (IGFBP-3) batch.
bAge at biopsy (continuous), IGFBP-3 batch, body mass index (continuous), menopausal status
(premenopausal/dubious; postmenopausal, no postmenopausal hormone use; postmenopausal, postmenopausal hormone use), histological category of benign
breast disease (proliferative without atypia, proliferative with atypia).
cMultivariate model 1 plus parity (nulliparous, parous), alcohol (none, < 1.5, 1.5 to 4.5, 4.5+
g/day).
dMultivariate model 2 plus square-root transformed insulin-like growth factor 1 (continuous).
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